Sickle cell disease (SCD) is a severe genetic blood disorder characterized by hemolytic
anemia, episodic vaso-occlusion, and progressive organ damage. Current management of …

Sickle cell disease is the most common inherited haematological disorder that leads to the
irreversible damage of multiple organs. Although sickling of red blood cells and vaso …

The primary β-globin gene mutation that causes sickle cell disease (SCD) has significant
pathophysiological consequences that result in hemolytic events and the induction of the …

This narrative review aims to highlight the current paradigm on pain management in sickle
cell vaso-occlusive crisis. It specifically examines the pathophysiologic mechanisms of sickle …

Sickle cell disease (SCD) is an inherited hemoglobinopathy that is caused by the presence
of abnormal hemoglobin S (HbS) in red blood cells, leading to alterations in red cell …

Venous thromboembolism (VTE) is common in patients with sickle cell disease (SCD). The
etiology of increased risk of VTE in SCD patients is multifactorial and is related to both …

Sickle cell disease (SCD) is associated with chronic activation of coagulation and an
increased risk of venous thromboembolism. Erythrocyte sickling, the primary pathologic …

The genetic and molecular basis of sickle cell disease (SCD) has long been characterized
but the pathophysiological basis has not been entirely defined. How a red cell hemolytic …

Sickle cell disease (SCD), the most common genetic hemolytic anemia worldwide, affects
250,000 births annually. In the United States, SCD affects approximately 100,000 …

Blood from patients with sickle cell disease contains microparticles (MP) derived from
multiple cell sources, including red cells, platelets, monocytes and endothelial cells. MP s …